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Research
he prevalence of systemic allergy to
native ant stings in Australia is as
high as 3% in areas where these
insects are commonly encountered, such as
Tasmania and regional Victoria.1,2 In one
large Tasmanian emergency department
study, ant sting allergy was the most com-
mon cause of anaphylaxis (30%), exceeding
cases attributed to bees, wasps, antibiotics
or food.3
Myrmecia pilosula (jack jumper ant [JJA])
is the major cause of ant sting anaphylaxis
in Tasmania.2 A double-blind, randomised
placebo-controlled trial has demonstrated
the effectiveness of JJA venom immuno-
therapy (VIT) to reduce the risk of sting
anaphylaxis, and an ongoing treatment and
research program has been established.4,5
Access to treatment outside Tasmania is
limited by inadequate knowledge of the
causative species in other regions and the
absence of diagnostic tests for other ant
species. Accurate diagnosis is further com-
plicated because the JJA is a “species com-
plex”, comprising seven closely related
species with almost identical morphology.
These were first recognised by chromo-
somal differences but can now be distin-
guished using subtle differences in
morphological characteristics.6
The objectives of the Australian Ant
Venom Allergy Study were to determine the
geographical distribution of the major ant
species associated with anaphylaxis
throughout Australia, and to examine the
feasibility of newly developed diagnostic
testing to confirm the diagnosis of allergy to
non-JJA ant species.
METHODS
Study population
In 2006 and 2007, we requested case refer-
rals from Australian doctors with allergy
practices by emailing all members of the
Australasian Society of Clinical Immunology
and Allergy, and from emergency medicine
specialists by emailing all Fellows of the
Australasian College for Emergency Medi-
cine. We also used press releases and stories
in regional newspapers and on radio and
television, and web search indexing with a
study home page, to encourage people with
ant sting allergy to contact us directly.
Inclusion criteria were a history of a gen-
eralised systemic allergic reaction to an iden-
tified or suspected ant sting. Cases were
excluded if investigation indicated that a
systemic reaction did not occur or that an
ant sting was not the cause. The human
research ethics committees of each investi-
gator’s institution granted ethics approval.
Participants gave written informed consent.
Clinical data
Participants identified the responsible ant
(where possible) from colour illustrations of
common species and completed a question-
naire, followed by a structured telephone or
face-to-face interview. We recorded partici-
pants’ age and sex, the geographical location
where each reaction occurred, reaction fea-
tures, a description of the insect and
whether it was clearly seen to sting or
implicated by circumstance (eg, seen
nearby), and a reaction severity grade of
mild (skin only), moderate (involvement of
additional organ systems) or severe (hypo-
tension or hypoxaemia).3 Serum samples
were obtained and stored at − 80° C until
analysis.
Entomological specimens, collection 
and identification
With the assistance of participants’ non-ant-
allergic family or friends, 2–4 specimens of
ant(s) were provided from each location
where systemic reactions had occurred. Ants
were not collected from the Northern Terri-
tory, northern Queensland or northern
Western Australia because few participants
came from these areas, nor from Tasmania,
as ants in that region are already well char-
acterised. Wherever possible, the investiga-
tors made field trips to collect additional
specimens for identification and whole ant
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nests (colonies) for venom extraction from
areas where stings had occurred. Ant colo-
nies were transported on dry ice, then stored
at − 80° C until venom sac dissection and
processing, as previously described.4,7,8
Specimens were identified by one of us
(R W T) and deposited in the Common-
wealth Scientific and Industrial Research
Organisation (CSIRO) Australian National
Insect Collection.
Venom extracts
After morphological identification, venoms
extracted from different sibling species of
the JJA species complex were analysed by
polyacrylamide gel electrophoresis accord-
ing to our previously established methods.9
Once homology of venoms from sibling
species was confirmed, we used a standard-
ised JJA extract produced by the Tasmanian
Jack Jumper Allergy Program for our
venom-specific IgE (sIgE) assays.7
For all other species, venom extracts from
the same species were pooled to create
reference venoms for use in sIgE assays, only
after both formal entomological identifica-
tion and confirmation of the presence of
identical bands on polyacrylamide gel elec-
trophoresis in venom samples from each
component colony.
Venom-specific IgE assays and 
determining reaction causation
A time-resolved fluorescence method, disso-
ciation-enhanced lanthanide fluoroimmu-
noassay  (DELFIA;  Wal lac ,  Turku,
Finland),10 was used to detect sIgE against a
panel of ant venoms relevant to each geo-
graphical region where sting reactions had
occurred. Venom panels for sIgE testing
were chosen for each region based on our
collected specimens and known distribu-
tions.11,12 We were unable to include species
if they were rarely encountered and we
could not obtain sufficient venom.
The cause of each reaction was attributed
using a combination of ant identification and
sIgE testing, as outlined in Box 1. A single
positive sIgE result allowed us to confirm a
clear ant description or, if there was some
uncertainty about the ant(s) described,
allowed us to decide between several possi-
ble causes. However, multiple positive sIgE
results (representing either cross-reactivity
or multiple sensitisations) required a high
degree of clinical certainty (visual identifi-
cation) before attributing causation.
Statistical analysis
Proportions were calculated with 95% confi-
dence intervals (binomial exact) (Stata, release
11; StataCorp, College Station, Tex, USA).
RESULTS
Three hundred and seventy-six participants
reported 735 systemic reactions. Basic
demographic and reaction data are shown in
Box 2. We identified 283 specimens of
stinging ants collected from locations where
reactions had occurred (Box 3). There were
four dominant ant species or groups, each
with characteristic morphology: (i) JJA spe-
cies complex; (ii) other jumper ants
(Myrmecia nigrocincta in New South Wales
and Queensland, Myrmecia ludlowi in WA);
(iii) bulldog ants (BDA) of the Myrmecia
gulosa species group; and (iv) Rhytidoponera
metallica (green-head ant [GHA]) (Box 4).
Venom-specific IgE results and reaction 
causation
Venoms used for sIgE testing for each region
are shown in Box 3. Serum samples from
325 participants (86%; 95% CI, 83%–90%)
were sIgE-positive to one or more venoms
relevant to the geographical regions where
the stings occurred. Reaction causes were
2 Participant demographics and 
reaction characteristics
Characteristic
Number of participants 376
Age in years, median (IQR) 46 (33–64)
Male 158 (42%)
Age in years at first reaction, 
median (IQR)
46 (19–58)
Years since last reaction, 
median (IQR)
1.7 (0.4–5.0)
Severity of worst reaction
Mild 22 (6%)
Moderate 150 (40%)
Severe 204 (54%)
IQR = interquartile range. ◆
1 Determining reaction causation in 376 participants with ant stings
DELFIA = dissociation-enhanced lanthanide fluoroimmunoassay. sIgE = venom-specific IgE. GHA = green-
head ant. JJA = jack jumper ant. BDA = bulldog ant. ◆
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designated for 299 participants (80%; 95%
CI, 75%–83%) (Box 1). For the remaining
77 participants (20%), 38 of whom were
stung in northern Australia, a reaction cause
could not be attributed.
Of the 299 participants for whom a cause
could be determined, 265 (89%; 95% CI,
84%–92%) had reacted to Myrmecia species
and 34 (11%; 95% CI, 8%–16%) to GHA.
No participant was judged as reacting clini-
cally to both GHA and Myrmecia species. Of
the 265 participants clinically reactive to
Myrmecia species, 186 (70%; 95% CI, 64%–
76%) reacted to jumper ants alone, 49 (18%;
95% CI, 14%–24%) to BDA alone and seven
(3%; 95% CI, 1%–5%) to both BDA and
jumper ants. For 23 (9%; 95% CI, 6%–
13%), the species or species group of
Myrmecia responsible could not be deter-
mined. Of the 193 who had reacted clinically
to jumper ants, this was JJA in 175 cases
(91%; 95% CI, 86%–94%), M. nigrocincta in
15 (8%; 95% CI, 4%–12%), M. ludlowi in
two, and both M. ludlowi and JJA in one case.
Geographical distribution of reactions
The geographical locations of reactions to
causative ants are mapped in Box 5. JJA
reactions occurred in Tasmania, southern
coastal WA, South Australia, Victoria and
southern coastal and mountainous regions of
NSW and the Australian Capital Territory.
The distribution of JJA sting reactions closely
mirrors that for entomological collection
records of specimens of the M. pilosula spe-
cies complex.12 Reactions to BDA occurred
in the same areas as JJA reactions and also
extended to more inland and northern parts
of NSW and further north in WA, as far as
Geraldton. M. ludlowi was also a cause of
reactions in the areas where BDA were found
in WA. M. nigrocincta and GHA reactions
were largely clustered around northern
coastal NSW and south-east Queensland.
Venom-specific IgE cross-reactivity and 
multiple sensitisations
We were unable to distinguish between sen-
sitisation to multiple ant species and true
cross-reactivity. However, some patients
were sIgE-positive to one venom or venom
group alone without positive results to other
venoms tested, indicating the presence of
unique allergens in these venoms — this
applied to 15 of 34 patients reacting to GHA
(44%), 55 of 176 reacting to JJA (31%), 5 of
15 reacting to M. nigrocincta (33%), one of
three reacting to M. ludlowi (33%), and 47 of
56 reacting to venom(s) of BDA (84%).
In sera tested for sIgE against multiple
venoms from BDA, the following patterns
were observed.
WA: With the exception of one sample
negative to Myrmecia nigriceps, all 18 serum
samples tested for reactions occurring in WA
were positive to all of Myrmecia gratiosa,
Myrmecia pavida and M. nigriceps venoms
with very similar quantitative titres. These
three venoms also had identical protein
bands on gel electrophoresis. Nine serum
samples were also sIgE-positive to Myrmecia
regularis.
SA and Victoria: Of 26 serum samples
tested for reactions in these states, 22 were
sIgE-positive to Myrmecia forficata venom,
of which 14 were also positive to Myrmecia
pyriformis, and 10 to M. nigriceps. Of the
remaining four sera, one was sIgE-positive
to M. nigriceps venom alone, one to M.
pyriformis venom alone, and two were posi-
tive to both these venoms. Five of eight sera
tested for reactions in Victoria were sIgE-
positive to Myrmecia simillima, but never to
this venom alone.
NSW/ACT/Queensland: All 13 serum sam-
ples tested for reactions occurring in these
regions were sIgE-positive to M. forficata
and/or M. nigriceps venoms. Ten were also
positive to one or more of the other venoms
of BDA for these regions.
DISCUSSION
We found Myrmecia species to be the pre-
dominant cause of ant sting anaphylaxis in
Australia. JJA stings were the most common
cause, followed by stings from species of
BDA, the GHA, and then the jumper ants M.
nigrocincta in northern NSW and Queens-
3 Ant species implicated in sting reactions, and venoms used for sIgE testing*
No. of specimens collected
Species Tas† SA Vic NSW/ACT Qld WA Total (%, 95% CI)
Jumper ants 
Jack jumper ant 102 44 14 1 161
Myrmecia nigrocincta 5 13 18
Myrmecia chasei 1 1
Myrmecia swalei 1 1
Myrmecia ludlowi 2 2
Total jumper ants — 102 44 19 13 5 183 (65%, 59%–70%)
Bulldog ants
Myrmecia forficata 2 2 4
Myrmecia pyriformis 8 4 12
Myrmecia brevinoda 1 1
Myrmecia nigriceps 1 1
Myrmecia tarsata 1 1
Myrmecia simillima 1‡ 1
Myrmecia gulosa 3 3
Myrmecia gratiosa 12 12
Myrmecia pavida 4 4
Myrmecia nigriscapa 1 1
Myrmecia regularis 1 1
Total bulldog ants — 11 6 6 0 18 41 (14%, 11%–19%)
Green-head ants — 1 0 12 32 0 45 (16%, 12%–21%)
Other stinging ants — 2 2 4 3 1 14§ (5%, 3%–8%)
Total — 116 52 41 48 24 283
sIgE = venom-specific IgE. Tas = Tasmania. SA = South Australia. Vic = Victoria. NSW = New South Wales. 
ACT = Australian Capital Territory. Qld = Queensland. WA = Western Australia. * Shaded cells indicate venoms 
used for sIgE testing. Sera were tested according to the location of participants’ reported reactions (ie, 
multiple regions if relevant). † Specimens were not collected from Tasmania, as ants in that region are already 
well characterised. ‡ This specimen was returned from an area close to the Victorian border; M. simillima was 
not encountered on field trips to any other regions of SA. § Rhytidoponera sp. (not R. metallica), 8; 
Odontomachus sp., 4 (includes 2 in Northern Territory); Aphaenogaster, 1; and Tetramorium, 1.  ◆
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land and M. ludlowi in WA. While our find-
ings are broadly consistent with a number of
previous reports,1,2,13-16 this is the first time
that it has been possible to confirm the
causative species using sIgE testing against
an extended panel of relevant venoms.
Our study has some limitations. Recruit-
ment into the study was potentially biased
because the doctors we targeted (allergists,
clinical immunologists and emergency phy-
sicians) tend to be in or near population
centres, and because of potentially variable
interest by regional media outlets. For prac-
tical reasons, we also did not obtain venom
extracts from far northern areas of Australia.
The causative species group could not be
confirmed in 20% of cases, mostly due to
negative sIgE results. Possible causes of this
include allergy to less common species for
which venom extracts were unavailable, and
false negative results because of relatively
poor sensitivity of serum sIgE assays com-
pared with intradermal skin testing (IDT).
The multicentre nature of our study pre-
cluded IDT, although it should be noted that
this is also an imperfect test.17
While substantial antigenic cross-reactiv-
ity and/or multiple sensitisations to different
venoms was observed,18 the frequency with
which sera were positive to only one of the
venoms or venom groups indicated the pres-
ence of venom allergens unique to each
species. In particular, it should be noted that
while the venoms of the various sibling
species of the M. pilosula species complex
appear to be homologous by gel electro-
phoresis, there are other jumper ants (M.
nigrocincta and M. ludlowi) with very differ-
ent venoms for which the currently available
JJA venom extract will not be useful for
diagnosis or VIT.
By contrast, the venoms of the M. gratiosa,
M. pavida and M. nigriceps BDA appear to be
practically identical. While the venom rec-
ognition patterns are more complex for
other BDA, all sera in our study were posi-
tive to one or more of M. forficata, M.
pyriformis and M. nigriceps. These three ven-
oms are therefore likely to include most or
all of the major BDA allergens.
A major challenge we encountered was
the large number of potentially allergenic
venoms, allergenic cross-reactivity between
venoms, and the potential for multiple sen-
sitisations from stings by different species
experienced by any one individual. This is
not uncommon when assessing patients
with insect venom allergy. Examining the
ability of different venoms to inhibit sIgE
binding to each other in each serum sample
4 Australian ant species that cause allergic reactions
A: A large bulldog ant (Myrmecia pyriformis) and a smaller jumper ant and (inset) a green-head 
ant (~ 6 mm long, dark black–metallic green). Jumper ants can be further divided on the basis of 
colouration as either a jack jumper ant (JJA) or another jumper ant. B: JJA, usually 10–12 mm 
long, black body with orange–yellow mandibles, and moves with short jerks and jumps. 
C: Another jumper ant, Myrmecia nigrocincta, which is similar in size and behaviour to the JJA 
but with bright red body segment(s). The jumper ants Myrmecia ludlowi, Myrmecia swalei and 
Myrmecia chasei have similar body colouration. D: A typical jumper ant nest, covered with small 
stones. E–H: Bulldog ants of the Myrmecia gulosa species group, 20–30 mm long and a variety 
of colours. E: Myrmecia gulosa, the prototype for the group; F: Myrmecia gratiosa, which 
predominates in the Darling Scarp area east of Perth, Western Australia; G: Myrmecia nigriceps; 
and H: Myrmecia forficata, which predominates in Tasmania. ◆
5 Geographical distribution of ant sting allergic reactions
M. = Myrmecia. ◆
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can distinguish the primary sensitising
venom, identify allergenically identical ven-
oms or confirm the presence of sensitisa-
tions to multiple venoms.19 However,
sensitisation with demonstrable sIgE does
not necessarily result in clinical reactivity.20
Thus, the presence of sIgE is only used to
confirm a diagnosis that has been made
from a clinical history including a descrip-
tion of the insect (if seen), circumstances of
the sting and a detailed knowledge of local
insect species.21
Management of sting anaphylaxis centres
on identification of the causative insect,
avoidance strategies where possible (eg, nest
removal, moving to a location where the
species is absent or less common), provision
of an emergency action plan, and VIT where
available. Although economic factors may
preclude the production of therapeutic ant
venom extracts for all species when only
small numbers of patients are affected, the
development of diagnostic sIgE assays will
help distinguish between allergy to native
ant species and allergy to other insect spe-
cies, and thus facilitate the accurate applica-
tion of VIT.
VIT is currently subsidised by the Phar-
maceutical Benefits Scheme (PBS) in Aus-
tralia for the treatment of honeybee and
wasp (Polistes and yellowjacket) allergy. JJA
VIT is currently funded in Tasmania by the
state government; the venom extract can be
supplied to interstate hospitals as an active
pharmaceutical ingredient for on-site for-
mulation and dispensing,22 but is not subsi-
dised by the PBS and the cost must be
covered in full by the hospitals and/or
patients. No venom extracts suitable for
human use are available for other Australian
ant species at this time. Future work in this
area should focus on confirming the appar-
ent antigenic homology of closely related
venoms and developing standardised venom
extracts for diagnostic and therapeutic use.
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